Work

Analyse en sous-groupe de l'efficacité du lénacapavir à la semaine 52 chez les PVVIH lourdement pré-traités

Year: 2023

Type: article

Source: Médecine et Maladies Infectieuses Formation

DOI: 10.1016/j.mmifmc.2023.03.186

Authors: O. Ogbuagu, S. Segal-Maure, E. DeJesus, A. Avihingsanon, C. Zurawski, O. Osiyemi, G.E. Crofoot, H. Wang, H. Dvory-Sobol, M. S Rhee, G. Barrière, J. Baeten, J.M. Molina

Institutions: Yale University, Orlando Immunology Center, Thai Red Cross Society, HIV Netherlands Australia Thailand Research Collaboration, Triple O Medical Services, Gilead Sciences (United States), Gilead Sciences (France), Université Paris Cité, Hôpital Lariboisière, Hôpital Saint-Louis

Language: French

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4376879974

FWCI:

Cites:

Cited by:

Related to: 10